Half Year 2025 Healius Ltd Earnings Call Transcript
Key Points
- Healius Ltd (ASX:HLS) reported a 10% increase in group revenue, with pathology revenue growing by 7% and Lumus imaging revenue up by 13.3%.
- EBITDA increased by 3.3% and EBIT rose significantly by 51% to $23.7 million.
- The company has successfully reduced collection center closures by 50%, improving customer service levels.
- Genomic diagnostics revenue grew by 45%, highlighting strong growth potential in emerging diagnostics.
- The sale of Lumus imaging for $965 million is expected to generate net proceeds in excess of $800 million, which will be used to repay debt and return surplus cash to shareholders.
- Despite revenue growth, margins remained flat due to increased labor costs from investments in staffing collection centers and call centers.
- Agilex Biolabs' performance was impacted by the US elections, resulting in flat revenue and a reduction in EBIT to $1.1 million.
- The pathology segment's revenue growth has not yet translated into higher earnings due to deliberate investments in labor.
- There are concerns about stranded costs post the sale of Lumus imaging, which may affect profitability.
- The company faces challenges with indexation and potential changes in government policy, such as the B12 and vitamin year-end changes.
Good morning, everyone, and welcome to our 2025 half-year results call. Since our full-year results in August last year, we have announced the sale of Lumus imaging for $965 million, and the management team have been focusing all efforts on embedding our new pathology strategy and operating models.
Whilst it is taking time to implement such wide-ranging changes, we have made significant progress on both fronts. Our transformation plan forms the backbone of the changes we are making in the business, and we will be providing more information on our plans and how these are very important building blocks for the future at our Investor Day in March.
This morning, we have announced our 1H '25 results, which were in line with guidance provided at the Annual General Meeting. Group revenue was up 10%, which comprised pathology revenue growth of 7%, Agilex revenue down slightly by 1.1%, and Lumus imaging revenue growth of 13.3%.
Underlying results for the period saw EBITDA up 3.3% and EBIT up by 51% to $23.7 million
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
